The Drug Eluting Stents Center

Filter Your Results

 

News

 

REAL PTX Data Show Similar Outcomes for DES and DCB With Bailout Stenting at 1 Year, Trend Favoring DES at 3 Years

February 14, 2019 -- Recent data published from the REAL PTX trial showed that drug-eluting stents (DESs) and drug-coated balloons (DCBs) with bailout stenting had similar saf…

No Evidence of Paclitaxel-Related Increased Mortality Found in Medicare Database Analysis at 600 Days

February 14, 2019 -- A study published online in JAMA Cardiology by Eric A. Secemsky, MD, et al showed no evidence of increased all-cause mortality following femoropopliteal a…

JACC Patient-Level Analysis of Medtronic DCB Studies Concludes That Mortality Is Not Correlated With Paclitaxel Exposure

January 31, 2019 -- Peter A. Schneider, MD, et al conducted a patient-level analysis of data from several independently adjudicated prospective studies involving Medtronic&nbs…

SCAI Issues Statement on the Association of Paclitaxel Devices and Mortality

January 25, 2019 -- The Society for Cardiovascular Angiography and Interventions (SCAI) has issued a statement on the recent study of the association between paclitaxel-elutin…

LINC 2019: Patient-Level Data Presentations at LINC Aim to Disprove Causality Between Paclitaxel and Increased Mortality

Attendees packed a special session to open LINC 2019 in Leipzig, Germany, to hear discussion of the recent meta-analysis published by Konstantinos Katsanos, MD, et al that sug…

A Roundtable Discussion on Results From the First Head-to-Head DES SFA Trial: IMPERIAL

With Michael R. Jaff, DO; Gary M. Ansel, MD, FACC; William A. Gray, MD; Steve Henao, MD, FACC, FACS; and Robert A. Lookstein, MD

January 2019—A multidisciplinary panel of PAD experts discuss the impact on patient care and the health care system and how these results may shift current treatment algorithms.

Discussing the IMPERIAL Data in Practice

With Yann Gouëffic, MD, PhD; and Andrew Holden, MBChB, FRANZCR, EBIR

January 2019—Two vascular experts share their reactions to hearing the results of the first head-to-head peripheral DES trial.

IMPERIAL 12-Month Full Cohort and Long Lesion Sub-Study Results

William A. Gray, MD; Additional commentary by Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA, FSIR

January 2019—Sustained drug-release in the SFA drives superior results.

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.